{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-113404","form_type":"8-K","ticker":"HURA","cik":"0001498382","company_name":"TuHURA Biosciences, Inc./NV","filed_at":"2024-10-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.596682+00:00","generated_at":"2026-05-30T17:54:15.091565+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Kintara stockholders approve TuHURA merger; FY2024 net loss $8.32M","bullets":["Stockholders approved merger with TuHURA on Oct 4, 2024; closing expected mid-October 2024.","Cash and equivalents $4.9M as of June 30, 2024.","FY2024 net loss $8.3M ($0.32 loss per share), improved from $14.6M ($9.27 loss) in FY2023.","REM-001 study dosed 4 patients; $2.0M NIH grant covers most costs; R&D expenses fell 71%."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-113404","json":"https://secwatch.observer/filing/0000950170-24-113404.json","markdown":"https://secwatch.observer/filing/0000950170-24-113404.md","text":"https://secwatch.observer/filing/0000950170-24-113404.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1498382/000095017024113404/0000950170-24-113404-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1498382/000095017024113404/ktra-20241007.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T17:54:15.091565+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}